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Introduction
Due to the shortage of human organs for allo-
transplantation, essential efforts aimed at de-
veloping a transgenic source animal (donor) for
animal-human xenotransplantation have been
performed over the last decade. Although man
is concordant with old world primates, and the
choice of this species would be an obvious way
to prevent hyperacute rejection, there are sev-
eral good reasons for preferring pigs to pri-
mates (Table 1). Therefore, concerns for future
maintenance problems should be related to the
pig. It can be questioned whether maintenance
conditions of the transgenic xenograft donor
pigs will differ significantly from non-trans-
genic pigs. Due to the fact that a xenograft
donor pig is not yet fully available, little factual
knowledge about this issue is available. How-
ever, in relation to a future xenograft donor pig
basic and applied research has already created
knowledge usable for the prediction of its
health and welfare. Transgenic knock out mice
partly equivalent to a future donor pig have ex-
isted for years, and basic knowledge on the
function of the strategic transgenes is also avail-
able. Therefore, essential information on the
impact of these modifications may be achieved
by combining this information. Basically, these
will be reared and cared for as for other pigs,
but two considerations may make the mainte-
nance principles different. Firstly, transgenesis
may have induced new health and welfare prob-
lems in these pigs, and secondly, the specialized
use of the pig may induce new hazards to the
xenograft recipients and even to mankind, as
such.
Potential health and welfare problems of a
future xeno-source pig
Several types of gene-modified pigs aimed at
avoiding complement activation against the al-
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T a  b  l  e  1 .  Advantages and disadvantages choosing between pig and primates as xenograft source animals.
Characteristic Primates Pigs
Hyperacute rejection No Yes
Breeding performance offspring/year/mother (app) 1 20
Knowledge on immunology and disease Moderate High
Risk of xenozoonotic infections High Moderate
Physiological compatibility High Moderate
Life span (years) 10 - 15 20 - 60
Size (kg) 5 - 15 10 - 300
pha-gal epitope have been produced, but so far,
only three types seem to be have a realistic fu-
ture as xenograft source animals: 
1. Pigs with complement regulatory factors
(CRF) inserted, 
2. Pigs with a targeted mutation of the galacto-
syltransferase gene, so-called alpha-gal
knock out pigs, and 
3. The combination of 1 and 2.
Both mice (7, 12, 18, 33) and pigs (12, 24)
transgenic for CRF's have been produced, and
within both species multiple transfection or
crossbreeding have been used to produce dou-
ble transgenic animals, either with two CRF's
(4, 6) or one CRF and one alpha-gal related
gene (5, 33). None of the papers report on any
pathological, behavioural, clinical or otherwise
welfare-related problems related to the pig car-
rying a human CRF. Animals transgenic for
such genes will still express their own species
specific CRF's, which will identify their organs
as species-homologue, while the organ is
placed in situ in the live xenograft source ani-
mal. Therefore, these transgenes are indeed less
likely to cause problems for the xenograft
donor, but closer examination of CRF trans-
genic animals are needed to state, whether, and
to which extent, they are affected by the trans-
genesis.
Also alpha-gal knock out animals are available
as both mice (28, 32) and pigs (10, 19). Dahl et
al. (9) have listed four possible health and wel-
fare consequences of this targeted mutation: 
• Reduced sperm adhesion to zona pellucida.
• Increased sensibility to sepsis
• Increased sensibility to autoimmune diseases
• Cataract formation 
Apart from these points, alpha-gal knock out
animals seem to have the same size, appearance
and clinical chemistry as their wild type litter
mates, and their organs do not seem to differ
macro- or microscopically (28, 31). After two
years of observation of alpha-gal knock out
mice in of one of the colonies the life span and
health status seem to be normal (22). So, only
little knowledge is available on health and wel-
fare of alpha-gal knock out pigs, apart from the
fact that they are viable.
Reduced sperm adhesion to zona pellucida
Gal transferases play an important role for the
attachment of spermatozoa to zona pellucida
(26, 27) by binding to N-acetylglucosamine
residues in the zona pellucida, while releasing
alternative substrates that prevent the binding
of other capacitated spermatozoa (25). It might,
therefore, be expected that it would be difficult
to produce homozygotic alpha-gal knock out
animals, because the alpha-gal depleted sperm
may not be able to bind to the zona pellucida
and thus prevent further entry of other sperma-
tozoa. Since two groups have reported the suc-
cessful production of alpha-gal knock out mice
(28, 32) these problems do not fully impair fer-
tilisation, but one group reports that matings
between heterozygous alpha-gal knock out car-
rier mice do not result in the expected 1:2:1 ra-
tio (28). At least, it is, therefore, reasonable to
assume that alpha-gal depleted spermatozoa are
less competitive due to the lack of the gal trans-
ferase, although not fully incapable of fertilisa-
tion. 
Increased sensibility to sepsis
Alpha-gal antibodies more frequently bind to
Enterobacteriaceae isolates from patients with
sepsis than to isolates from the stool of healthy
humans (14). In these patients these antibodies
do not seem to initiate complement-mediated
lysis of alpha-gal epitope containing bacteria.
Neither do they provide a protected site for C3
deposition. In the same way, bacteria isolated
from the gallstones of patients with sepsis, have
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been shown to always express the a-gal epitope
(34). These findings seem to indicate, that the
alpha-gal antibodies are capable of protecting
certain bacteria from complement-mediated ly-
sis, and pigs with circulating alpha-gal antibod-
ies may therefore express a higher degree of
susceptibility to septicaemias caused by e.g.
Escherichia coli.
Increased sensibility to autoimmune diseases
In human patients elevated titres of alpha-gal
antibodies have been found in patients suffering
from diseases with autoimmune elements, such
as thyreoiditis. This could be due to the expo-
sure of cryptic alpha-gal epitopes present in
cells of certain tissues, e.g. thyroidea (11), or
rearrangement and subsequent increased ex-
pression caused by binding of alpha-gal anti-
bodies to the epitope on the cell surface (29),
but it may also simply be an artefact caused by
alpha-gal epitopes present on thyroid tissues
used for bioassays (30). Elevated titers of al-
pha-gal antibodies have also been found in
rheumatoid arthritis patients with kidney dam-
age after treatment with gold and/or D-penicil-
lamine (20).
Cataract formation
One of the two groups producing alpha-gal
knock out mice reports that these animals de-
velop cortical cataracts at the age of 4-6 weeks
(28). Cataract formation is associated with sig-
nificant membrane leakage, suggesting that the
mouse lens is very sensitive to biochemical dis-
turbance (22). No such changes are reported by
the other group (32). 
Potential health and welfare problems of
xenograft recipients
Most concern about xenozoonotic infections is
obviously related to the risk of activating
porcine endogenous retroviruses (PERV) in the
recipients, but it is unlikely that this risk can be
dealt with in the production and maintenance
process. However, it is clear that ordinary
zoonotic infections known to be present in pigs,
such as Salmonella sp., influenzaviruses, en-
cephalymyocarditis virus and rotaviruses may
compose a risk for the recipients. Furthermore,
as pig production is of major economic impact
in a number of countries, it is unacceptable to
have human xenograft recipients as carriers of
unwanted porcine infections. These are both
problems to be solved in the production phase. 
Health protection in xenograft donor pigs
The main problem in the production of
xenograft source pigs to be dealt with in the
production phase seems to be protection against
infections. Protective systems with terms, such
as Specific Pathogen Free (SPF) or Minimal
Disease (MD), exist for pig production in many
Western countries. Most of such regulations are
aimed at improving agricultural economy
rather than the more sophisticated use of the
porcine organs for xenotransplantation. E.g.
Danish SPF regulations ensure protection
against Mycoplasma hyopneumoniae, Acti-
nobacillus pleuropneumonia Type 2, Sarcoptes
scabiei, Serpulina hyodysenteriae and toxin-
producing Pasteurella multocida (1). Agents of
interest in xenotransplantation, such as influen-
zaviruses and Erysipelothrix rhusiopathiae are
common in these pig herds (2). Therefore, com-
mercial laboratory pig producers as well as
xenotransplantation research facilities gener-
ally follow even stricter regimes (16).
Pigs for upstart of breeding are produced by
caesarian section or embryo transfer. Breeding
and rearing is performed behind barriers that
protect against unwanted infections. The staff
needs to shower into the facility, redress in de-
contaminated clothes, and they are under strict
quarantine if they have been in contact with
other pigs. Diet, equipment and materials are
decontaminated through autoclaves or chemi-
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cal locks, and the herd is currently screened for
a high number of agents by a range of methods
(17), e.g. as proposed for sentinel animals by
the Federation of European Laboratory Animal
Science Associations (23). Such regimes are
under current development, as it may still prove
difficult to remain free of any kind of porcine
infection in countries where there is major pro-
duction of pigs for agricultural purposes, and
consequently inhabitants have massive contact
with porcine products.
If alpha-gal antibodies are capable of protecting
Enterobacteriaceae spp. from complement-
mediated lysis (14), this is very likely to be-
come a problem in colonies of alpha-gal knock
out pigs. Septicaemias caused by Enterobacte-
riaceae spp. are one of the most common
causes of death in pig herds. It may occur in
both piglets and young pigs (3) and as many as
2% of the population may die from this (8). E.
coli is the most common cause, but also another
alpha-gal epitope expressing bacterium, Kleb-
siella pneumoniae, is a common cause (13, 21).
In the pig, all components of the native and the
acquired immune systems develop in utero and
are functional at birth, although less efficient
(15). Therefore, lacking the ability to lyse sep-
ticaemic bacteria by complement may increase
the incidence of septicaemias. If this is the case,
this problem has to be dealt with in two ways.
Either, the production systems must be changed
to reduce factors, such as stocking densities and
post-weaning stress compared to ordinary pig
herds, or the pigs have to be bred in isolators,
i.e. systems with no contact with the external
environment or with humans which ensures full
control of all infections. The latter will be time
consuming and expensive.
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